E-mail a Wiley Online Library Link

Jason C. Barnett, Angeles Alvarez Secord, David E. Cohn, Charles A. Leath III, Evan R. Myers and Laura J. Havrilesky Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer Cancer 119

Article first published online: 6 AUG 2013 | DOI: 10.1002/cncr.28283

The addition of bevacizumab to standard chemotherapy for the primary treatment of ovarian cancer is not cost effective by common willingness-to-pay thresholds. However, when bevacizumab is incorporated into treatment only for patients with a poor prognosis or for those with a positive predictive genetic test, it may be a more cost-conscious approach.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

Choose captcha format: Image or Audio. Click here if you need help.